While Takeda is eliminating 4,500 roles across its global operations, the company has some 2,200 jobs currently open for hiring, for which internal candidates will be prioritized.

Original title: “Takeda’s ‘transformation program’ leaves 4,500 jobless”

Asgard has appointed Prof Dr Wolfram Brugger as CMO

Original title: “Prof Dr Wolfram Brugger”

While average job postings live on BioSpace have increased year over year for nearly every month of 2026, the number of employees affected by made or planned layoffs by the end of that same period nearly matched what was seen in 2025.

Original title: “Hiring outlook: job opportunities on BioSpace rise YOY, but layoffs affect thousands”

Looking for a biopharma job in California? Check out the BioSpace list of 17 companies hiring life sciences professionals like you.

Original title: “17 companies hiring in California”

MacroGenics is selling the manufacturing plant to Bora, a Taiwan-based CDMO, to raise cash to support the progress of its drug development pipeline.

Original title: “Bora inks $122.5M takeover of MacroGenics facility to further US expansion”

After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. But analysts don’t expect much relief, no matter who helms the agency.

Original title: “UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged”

It’s official: FDA Commissioner Marty Makary is out at the FDA after reports of his ouster emerged late last week; Sanofi is reportedly having challenges with one of the FDA’s new signature programs; and biopharma CEOs’ multimillion-dollar salaries ticked up again this year. Who made the most in 2025?

Original title: “Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay”

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies.

Original title: “Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching”

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets.

Original title: “AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever”

Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.

Original title: “Scientist as strategist: expanding the role beyond the bench”

European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.

Original title: “Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue?”

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.

Original title: “FDA chief Marty Makary resigns from agency, ending tumultuous tenure”

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

Original title: “Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug”